[Actovegin in the treatment of brain injuries of mild and moderate severity].
Sixty-eight patients, including 32 patients of the main group who received aktovegin in addition to standard therapy and 36 patients of the control group with standard therapy only, have been studied. In both groups, various traumatic injuries (small focal injuries, subdural and epidural hematomas, traumatic subarachnoid hemorrhages, a combination of covering hematoma and small focal injuries) have been found. Aktovegin has been used in drops in dosage 400 mg per 200 ml physiological solution for 10 days. A comparative analysis of clinical data and results of instrumental studies (EEG, CT etc) in the main and control groups gives grounds to conclude that the use of aktovegin in the complex with standard therapy improves the course of brain injuries thus promoting the earlier compensation of disturbed functions and shortening the terms of treatment. The regress of asthenic symptoms as well as positive EEG changes are most pronounced.
Talypov
A E
AE
Ioffe
Iu S
IuS
Miatchin
M Iu
MIu
Kuksova
N S
NS
D000293:Adolescent; D000328:Adult; D001930:Brain Injuries / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000627:therapeutic use*; D004569:Electroencephalography; D006418:Heme / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D012720:Severity of Illness Index; D014057:Tomography, X-Ray Computed
D000697:Central Nervous System Stimulants; D006418:Heme; C015646:Actovegin